Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
In: 10.1007/s00259-021-05237-y

Ereignis
Veröffentlichung
(wo)
Aachen
(wer)
Universitätsbibliothek der RWTH Aachen
(wann)
2021
Urheber
Manafi-Farid, Reyhaneh
Harsini, Sara
Saidi, Bahare
Ahmadzadehfar, Hojat
Herrmann, Ken
Briganti, Alberto
Walz, Jochen
Beheshti, Mohsen

DOI
10.18154/RWTH-CONV-248446
URN
urn:nbn:de:101:1-2023052501404768180177
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
25.03.2025, 13:49 MEZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Manafi-Farid, Reyhaneh
  • Harsini, Sara
  • Saidi, Bahare
  • Ahmadzadehfar, Hojat
  • Herrmann, Ken
  • Briganti, Alberto
  • Walz, Jochen
  • Beheshti, Mohsen
  • Universitätsbibliothek der RWTH Aachen

Entstanden

  • 2021

Ähnliche Objekte (12)

Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer

An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T

⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer

Hochschulschrift

⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer

Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer

Safety and survival utcomes of 177 Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate Cancer with prior 223 Ra treatment: the RALU study

Safety and survival utcomes of 177 Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate Cancer with prior 223 Ra treatment: the RALU study

Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement

Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement

[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer

[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer

Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer

Verbundene Objekte